Valuation: Glenmark Pharmaceuticals Limited

Market Cap 743B 7.91B 7.19B 6.64B 6B 11.32B 11.72B 79.88B 31.65B 399B 29.69B 29.07B 1,263B P/E 2027 *
35x
P/E 2028 * 27x
Enterprise Value 731B 7.78B 7.07B 6.53B 5.9B 11.14B 11.53B 78.57B 31.13B 392B 29.21B 28.59B 1,242B EV / Sales 2027 *
4.31x
EV / Sales 2028 * 3.7x
Free-Float
51.04%
Yield 2027 *
0.16%
Yield 2028 * 0.15%
1 day-0.61%
1 week-2.25%
Current month+13.84%
1 month+18.40%
3 months+12.36%
6 months+11.84%
Current year+28.58%
1 week 2,608.8
Extreme 2608.8
2,689.2
1 month 2,101.6
Extreme 2101.6
2,714
Current year 1,842
Extreme 1842
2,714
1 year 1,818
Extreme 1818
2,714
3 years 761
Extreme 761
2,714
5 years 348.5
Extreme 348.5
2,714
10 years 161.65
Extreme 161.65
2,714
Manager TitleAgeSince
Chief Executive Officer 57 31/12/1999
Director of Finance/CFO 54 26/05/2025
President - 14/09/2023
Director TitleAgeSince
Director/Board Member 58 -
Chairman 57 11/05/2011
Director/Board Member 86 13/08/2009
Change 5-day change 1-year change 3-year change Capi.($)
-0.62%-2.25%+40.02%+237.25% 7.91B
-0.82%+1.40%+39.64%+143.17% 1,275B
-1.12%+0.16%+44.21%+88.24% 680B
-0.16%+0.43%+26.76%+113.01% 521B
-0.17%+2.04%+43.06%+72.81% 389B
-2.23%-2.89%+55.47%+41.64% 356B
-0.47%+1.72%+30.01%+63.11% 305B
-0.66%-0.23%+3.71%+38.05% 287B
-0.72%-0.63%+37.29%+71.87% 250B
-0.30%-1.03%+34.04%+124.88% 208B
Average -0.73%+0.31%+35.42%+99.40% 428B
Weighted average by Cap. -0.78%+0.76%+36.92%+98.28%

Financials

2027 *2028 *
Net sales 169B 1.8B 1.64B 1.51B 1.37B 2.58B 2.67B 18.21B 7.22B 90.9B 6.77B 6.63B 288B 188B 2B 1.82B 1.68B 1.52B 2.87B 2.97B 20.22B 8.01B 101B 7.52B 7.36B 320B
Net income 20.44B 218M 198M 183M 165M 311M 322M 2.2B 871M 10.97B 817M 799M 34.74B 27.35B 291M 265M 245M 221M 417M 432M 2.94B 1.17B 14.68B 1.09B 1.07B 46.5B
Net Debt -12.25B -130M -119M -110M -98.94M -187M -193M -1.32B -522M -6.58B -490M -479M -20.83B -47.16B -502M -456M -422M -381M -719M -744M -5.07B -2.01B -25.31B -1.88B -1.84B -80.17B
Projected Income Statement - Annual - Glenmark Pharmaceuticals Limited
Logo Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Employees
16,946
Date Price Change Volume
17/11/26 ₹2,616.60 -0.62% 138,243
16/11/26 ₹2,632.90 -0.27% 351,491
13/11/26 ₹2,640.00 -0.74% 440,861
12/11/26 ₹2,659.80 -0.65% 904,182
11/11/26 ₹2,677.20 +0.23% 665,196
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - Glenmark Pharmaceuticals Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,632.90INR
Average target price
2,659.55INR
Spread / Average Target
+1.01%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Glenmark Pharmaceuticals Limited
  1. Stock Market
  2. Stocks
  3. GLENMARK Stock